These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 24587245)

  • 1. Stathmin protein level, a potential predictive marker for taxane treatment response in endometrial cancer.
    Werner HM; Trovik J; Halle MK; Wik E; Akslen LA; Birkeland E; Bredholt T; Tangen IL; Krakstad C; Salvesen HB
    PLoS One; 2014; 9(2):e90141. PubMed ID: 24587245
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictive value of microtubule associated proteins tau and stathmin in patients with nonmuscle invasive bladder cancer receiving adjuvant intravesical taxane therapy.
    Wosnitzer MS; Domingo-Domenech J; Castillo-Martin M; Ritch C; Mansukhani M; Petrylack DP; Benson MC; McKiernan JM; Cordon-Cardo C
    J Urol; 2011 Nov; 186(5):2094-100. PubMed ID: 21944130
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High stathmin expression is a marker for poor clinical outcome in endometrial cancer: An NRG oncology group/gynecologic oncology group study.
    Reyes HD; Miecznikowski J; Gonzalez-Bosquet J; Devor EJ; Zhang Y; Thiel KW; Samuelson MI; McDonald M; Stephan JM; Hanjani P; Guntupalli S; Tewari KS; Backes F; Ramirez N; Fleming GF; Filiaci V; Birrer MJ; Leslie KK
    Gynecol Oncol; 2017 Aug; 146(2):247-253. PubMed ID: 28532857
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High phospho-Stathmin(Serine38) expression identifies aggressive endometrial cancer and suggests an association with PI3K inhibition.
    Wik E; Birkeland E; Trovik J; Werner HM; Hoivik EA; Mjos S; Krakstad C; Kusonmano K; Mauland K; Stefansson IM; Holst F; Petersen K; Oyan AM; Simon R; Kalland KH; Ricketts W; Akslen LA; Salvesen HB
    Clin Cancer Res; 2013 May; 19(9):2331-41. PubMed ID: 23538402
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Specific kinesin expression profiles associated with taxane resistance in basal-like breast cancer.
    Tan MH; De S; Bebek G; Orloff MS; Wesolowski R; Downs-Kelly E; Budd GT; Stark GR; Eng C
    Breast Cancer Res Treat; 2012 Feb; 131(3):849-58. PubMed ID: 21479552
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stathmin overexpression identifies high-risk patients and lymph node metastasis in endometrial cancer.
    Trovik J; Wik E; Stefansson IM; Marcickiewicz J; Tingulstad S; Staff AC; Njolstad TS; ; Vandenput I; Amant F; Akslen LA; Salvesen HB
    Clin Cancer Res; 2011 May; 17(10):3368-77. PubMed ID: 21242118
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High expression of stathmin 1 is a strong prognostic marker in oral squamous cell carcinoma patients treated by docetaxel-containing regimens.
    Harada K; Ferdous T; Harada T; Ueyama Y
    Clin Exp Med; 2017 Feb; 17(1):45-50. PubMed ID: 26590596
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emerging role of taxanes in adjuvant and neoadjuvant therapy for breast cancer: the potential and the questions.
    Goble S; Bear HD
    Surg Clin North Am; 2003 Aug; 83(4):943-71. PubMed ID: 12875604
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Retrospective analysis of second-line chemotherapy outcomes with paclitaxel or docetaxel in correlation with STMN1 polymorphism in advanced non-small cell lung cancer patients.
    Powrózek T; Mlak R; Krawczyk P; Bartoń S; Biernacka B; Małecka-Massalska T; Milanowski J
    Clin Transl Oncol; 2016 Jan; 18(1):33-9. PubMed ID: 26148901
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Taxane resistance in breast cancer: mechanisms, predictive biomarkers and circumvention strategies.
    Murray S; Briasoulis E; Linardou H; Bafaloukos D; Papadimitriou C
    Cancer Treat Rev; 2012 Nov; 38(7):890-903. PubMed ID: 22465195
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nab-Paclitaxel in Metastatic Breast Cancer: Defining the Best Patient Profile.
    González-Martín A; Alba E; Ciruelos E; Cortés J; Llombart A; Lluch A; Andrés R; Álvarez I; Aramendía JM; de la Peña FA; Barnadas A; Batista N; Calvo L; Galve E; García-Palomo A; García-Sáenz JÁ; de la Haba J; López R; López-Vivanco G; Martínez-Jáñez N; de Dueñas EM; Plazaola A; Rodríguez-Lescure Á; Ruiz M; Sánchez-Rovira P; Santaballa A; Seguí MÁ; Tusquets I; Zamora P; Martín M
    Curr Cancer Drug Targets; 2016; 16(5):415-28. PubMed ID: 26278712
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Taxanes for breast cancer: an evidence-based review of randomized phase II and phase III trials.
    Sparano JA
    Clin Breast Cancer; 2000 Apr; 1(1):32-40; discussion 41-2. PubMed ID: 11899388
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tubulin interacting agents: novel taxanes and epothilones.
    Agrawal NR; Ganapathi R; Mekhail T
    Curr Oncol Rep; 2003 Mar; 5(2):89-98. PubMed ID: 12583825
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Taxane-mediated radiosensitization derives from chromosomal missegregation on tripolar mitotic spindles orchestrated by AURKA and TPX2.
    Orth M; Unger K; Schoetz U; Belka C; Lauber K
    Oncogene; 2018 Jan; 37(1):52-62. PubMed ID: 28869599
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Estrogen receptor alpha (ESR1)-signaling regulates the expression of the taxane-response biomarker PRP4K.
    Lahsaee S; Corkery DP; Anthes LE; Holly A; Dellaire G
    Exp Cell Res; 2016 Jan; 340(1):125-31. PubMed ID: 26712520
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value of organic anion transporting polypeptide 1B3 and copper transporter 1 expression in endometrial cancer patients treated with paclitaxel and carboplatin.
    Ogane N; Yasuda M; Kameda Y; Yokose T; Kato H; Itoh A; Nishino S; Hashimoto Y; Kamoshida S
    Biomed Res; 2013 Jun; 34(3):143-51. PubMed ID: 23782748
    [TBL] [Abstract][Full Text] [Related]  

  • 17. miR-130a activates apoptotic signaling through activation of caspase-8 in taxane-resistant prostate cancer cells.
    Fujita Y; Kojima T; Kawakami K; Mizutani K; Kato T; Deguchi T; Ito M
    Prostate; 2015 Oct; 75(14):1568-78. PubMed ID: 26074357
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of TOP2A as a Predictive Marker for Endometrial Cancer With Taxane-Containing Adjuvant Chemotherapy.
    Ito F; Furukawa N; Nakai T
    Int J Gynecol Cancer; 2016 Feb; 26(2):325-30. PubMed ID: 26588239
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The determination of changes in the expression of genes for selected specific transcriptional factors in in vitro ductal breast cancer cells under the influence of paclitaxel.
    Ziaja-Sołtys M; Rzymowska J
    Cell Mol Biol Lett; 2011 Dec; 16(4):610-24. PubMed ID: 21909792
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization and detection of cellular and proteomic alterations in stable stathmin-overexpressing, taxol-resistant BT549 breast cancer cells using offgel IEF/PAGE difference gel electrophoresis.
    Balasubramani M; Nakao C; Uechi GT; Cardamone J; Kamath K; Leslie KL; Balachandran R; Wilson L; Day BW; Jordan MA
    Mutat Res; 2011 Jun; 722(2):154-64. PubMed ID: 20816848
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.